Drug intelligence / Profile preview

Resitev

Development stage: Unknown
Lead developer: Bioquest Pharma
Modality: Small Molecules
Administration: Ophthalmic

Overview

Resitev is a marketed generic ophthalmic formulation developed by Bioquest Pharma. It is part of the company's portfolio of finished generic ophthalmic therapies, which includes various eye drops, gels, and ointments. Detailed information regarding its specific active pharmaceutical ingredient, molecular target, and primary clinical indication is not publicly disclosed.

Brand names: Resitev

Beyond the preview

Go deeper on Resitev.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resitev.

Explore the full profile